A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

High-risk Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia (CMML)
AML - Acute Myeloid Leukemia
Chronic Myeloid Leukemia

Interventions

DRUG: CBX-250

Sponsor

Crossbow Therapeutics, Inc.